These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 6835381)

  • 1. Hybrid vaccinia virus for mass hepatitis immunization?
    Beale AJ
    Nature; 1983 Apr; 302(5908):476-7. PubMed ID: 6835381
    [No Abstract]   [Full Text] [Related]  

  • 2. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen.
    Smith GL; Mackett M; Moss B
    Nature; 1983 Apr; 302(5908):490-5. PubMed ID: 6835382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A recombinant vaccinia virus expressing the middle preS2-S envelope protein of the hepatitis B virus. The induction of humoral and cellular immunity by the immunization of laboratory animals].
    Beliaev AS; Dmitriev IP; Ignat'ev GM; Mizenko GA; Putintseva NI; Sabirov AN; Samukov VV; Semënova LN; Ammosov AD; Rukavishnikov MIu
    Dokl Akad Nauk SSSR; 1990; 314(2):488-91. PubMed ID: 2265587
    [No Abstract]   [Full Text] [Related]  

  • 4. Live recombinant vaccines using genetically engineered vaccinia virus.
    Paoletti E; Perkus ME; Piccini A
    Antiviral Res; 1985; Suppl 1():301-7. PubMed ID: 3866514
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatitis B vaccine.
    Eder G; McDonel JL; Dorner F
    Prog Liver Dis; 1986; 8():367-94. PubMed ID: 3520664
    [No Abstract]   [Full Text] [Related]  

  • 6. Improved recombinant LC16m0 or LC16m8 vaccinia virus successfully expressing hepatitis B surface antigen.
    Watanabe K; Kobayashi H; Kajiyama K; Morita M; Yasuda A; Gotoh H; Saeki S; Sugimoto M; Saito H; Kojima A
    Vaccine; 1989 Feb; 7(1):53-9. PubMed ID: 2718607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Priming effect of recombinant vaccinia virus coding for the middle hepatitis B surface antigen.
    Hamsíková E; Závadová H; Kutinová L; Ludvíková V; Krchnák V; Némecková S; Vonka V
    Arch Virol; 1990; 113(3-4):283-9. PubMed ID: 2222186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant vaccinia viruses as live vaccines.
    Smith GL
    Haematol Blood Transfus; 1987; 31():362-6. PubMed ID: 3443401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant vaccinia for prevention of hepatitis B.
    Beale J
    Nature; 1984 Sep 6-11; 311(5981):12-3. PubMed ID: 6472459
    [No Abstract]   [Full Text] [Related]  

  • 10. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.
    Paoletti E; Lipinskas BR; Samsonoff C; Mercer S; Panicali D
    Proc Natl Acad Sci U S A; 1984 Jan; 81(1):193-7. PubMed ID: 6320164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Isolation of a recombinant vaccinia virus based on the LIVP strain inducing the surface antigen of the hepatitis B virus].
    Al'tshteĭn AD; Zakharova LG; Loparev VN; Pashvykina GV; Gorodetskiĭ SI
    Dokl Akad Nauk SSSR; 1985; 285(3):696-9. PubMed ID: 4092585
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant vaccinia viruses as new live vaccines.
    Smith GL; Mackett M; Moss B
    Biotechnol Genet Eng Rev; 1984; 2():383-407. PubMed ID: 6100668
    [No Abstract]   [Full Text] [Related]  

  • 13. Newer directions in vaccine development and utilization.
    Hilleman MR
    J Infect Dis; 1985 Mar; 151(3):407-19. PubMed ID: 2982958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic properties of vaccinia virus and of the virus recombinant strains expressing heterologous genes.
    Chelyapov NV; Antonova TP; Yanova NN; Chernos VI
    Acta Virol; 1988 Sep; 32(5):409-16. PubMed ID: 2904735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of antibody formation to the vaccinia virus in human subjects and rabbits in response to the administration of a recombinant vaccinia-hepatitis B vaccine].
    Cheliapov NV; Chernos VI; Andzhaparidze OG
    Vopr Virusol; 1988; 33(2):175-9. PubMed ID: 2842961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experimental study of residual virulence of viral vaccine strains].
    Makhlaĭ AA; Bektimirov TA; Borisevich SV; Mikhaĭlov VV; Perekrest VV; Podkuĭko VN; Kirillov VB; Levitov AT; Ruchko VM
    Vopr Virusol; 1999; 44(2):75-8. PubMed ID: 10358902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tomorrow's hepatitis B vaccines. Arie Zuckerman discusses hepatitis B vaccines of the future and the impact of AIDS on immunization.
    Zuckerman AJ
    Vaccine; 1987 Sep; 5(3):165-7. PubMed ID: 3314219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Double recombinants of the vaccinia virus expressing hepatitis B virus surface antigen and herpes simplex virus thymidine kinase].
    Al'tshteĭn AD; Andzhaparidze OG; Antonova TP; Baev AA; Baĭsar D
    Dokl Akad Nauk SSSR; 1986; 289(6):1493-6. PubMed ID: 3021422
    [No Abstract]   [Full Text] [Related]  

  • 19. [Current status of the problem of viral hepatitis B prophylaxis].
    Golosova TV; Vlasikhina EM
    Probl Gematol Pereliv Krovi; 1980 Sep; 25(9):49-55. PubMed ID: 6999496
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity.
    Hutchings CL; Gilbert SC; Hill AV; Moore AC
    J Immunol; 2005 Jul; 175(1):599-606. PubMed ID: 15972697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.